What is the outlook for the CSL (ASX:CSL) share price?

Where to next for CSL shares?

| More on:
ResMed share price healthcare asx share price flat represented by doctor shrugging

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has had an…. interesting few years. Since topping out at its all-time high of nearly $343 a share back in February 2020, CSL shares have more or less treaded water ever since.

At yesterday's closing share price of $290.13 a share, CSL is 'only' up 1.8% in 2020 so far. That doesn't look great against the broader S&P/ASX 200 Index (ASX: XJO), which has managed a far healthier 9.34% in 2021. CSL is also up a very muted 2.6% over the past 12 months. Again this doesn't compare too favourably against the ASX 200, which is up more than 20% over the same period.

This might come as a surprise to many investors. Prior to 2020, CSL was known as a red hot, but still blue chip, growth share. It managed gains of roughly 50% in 2019, more than 30% in 2018 and around 40% in 2017. So a retreat into single-digit numbers is certainly a sea change for this healthcare company. As is its withdrawal into market-trailing returns.

CSL had a rough time with the outbreak of the pandemic last year. It's experienced issues with its blood plasma collections for one. It also had a potential vaccine candidate, developed in partnership with the University of Queensland, shelved last year.

But where to now for the CSL share price?

Is the CSL share price a buy today?

One broker who thinks there might be some small upside left in CSL shares is investment bank Goldman Sachs. Goldman currently has a 12-month share price target of $305 for CSL. Albeit with the caveat of a current 'neutral' rating.

The broker notes the ongoing sluggishness of CSL's plasma collection business, as well as what it sees as "consecutive years of single-digit earnings growth" as the primary reasons behind this rating.

Goldman reckons there is "a long road to recovery" for the company's plasma collections, which remain well below pre-COVID levels. Further, the bank is concerned that low earnings growth rates are not accurately reflected in the current CSL share price.

Even so, if Goldman's share price prediction proves accurate, it implies a potential upside of 5.1% over the next 12 months.

My Fool colleague James recently discussed the predictions of two other brokers recently. He noted that both Citi and Credit Suisse had slightly higher share price targets on CSL right now, both at $310 a share.

At the current CSL share price, the company has a market capitalisation of $132.05 billion. It also has a price-to-earnings (P/E) ratio of 36.8, and a trailing dividend yield of 0.97%.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

drug capsule opening up to reveal dollar signs signifying rising asx share price
Healthcare Shares

3 ASX healthcare shares going gangbusters on Thursday

Investors are sending these ASX healthcare stocks soaring today. But why?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Is it time to cash in on Sigma shares?

Shares have extended after the Chemist Warehouse merger.

Read more »

Person holding Australian dollar notes, symbolising dividends.
Healthcare Shares

Buy this ASX 200 share that is swimming in cash

Bell Potter sees potentially big returns on offer from this cashed-up stock.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Are CSL shares a buy after the biotech's FY25 forecasts?

Brokers continue to weigh in.

Read more »

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Are Wesfarmers or Sigma shares a better buy in the pharmacy arena?

These two stocks are both leaders in the industry.

Read more »

A young man goes over his finances and investment portfolio at home.
Healthcare Shares

Down 20%, is the NIB share price undervalued?

Here's what Goldman Sachs is saying about this blue chip stock.

Read more »

four excited doctors with their hands in the air
Healthcare Shares

Sigma Healthcare shares rocket 39% on Chemist Warehouse merger approval

The ACCC doesn't believe the company's merger with Chemist Warehouse will lessen competition.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

ASX 200 healthcare stock rockets on $75 million news

This marks another positive step for the company.

Read more »